Reuters logo
BRIEF-Amunix says Versartis gets PMDA approval in Japan to initiate enrollment for phase 3 study of Somavaratan in pediatric patients
October 17, 2016 / 1:22 PM / a year ago

BRIEF-Amunix says Versartis gets PMDA approval in Japan to initiate enrollment for phase 3 study of Somavaratan in pediatric patients

Oct 17 (Reuters) - Versartis Inc

* Amunix says Versartis has been granted approval in Japan by PMDA to initiate enrollment for its phase 3 study of Somavaratan in pediatric patients

* Phase 3 trial of J14VR5 is expected to be completed in Q3 of 2017, with topline data expected in 2018. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below